(131)~I一碘化油肝动脉灌注体内分布代谢的动物实验研究

Distribution and Metabolism of ^(131)l-Lipiodol after Hepatic Artery Infusion in Dog

为保证中、晚期肝癌的非手术疗法—肝动脉灌注^(131)I—碘化油的安全性,用^(131)I—标记碘化油给予实验犬4只进行动脉灌注,以观察体内分布、代谢.肝脏分布为74.38%～91.36%,经微循环达双肺仅为2.45%～8.57%.^(131)I—碘化油在肝、肺的有效半衰期分别为4、35±0.62天和5.23±0.88天.主要由肾脏排出,每天排泄量相对恒定,为注入剂量的2.6%～5.7%.由类便排泄的活性甚微,每日排泄仅为注入量的0.01%左右.结果表明^(131)I—碘化油行肝动脉灌注治疗中、晚期肝癌不会造成肝外器官损伤.

In order to evaluate the sal'ety of 131-Lipiodol infusion via hepatic artery in advanced liver cancer,the distribution and metabolism of the 131 I-Lipiodoi after the infusion was observed in 4 dogs. The results showed that 74. 38%-91. 35% of the lipiodol remained in the liver and 2. 45%-S. 57% in the lung. The half-life of the lipiodo! in liver and lung were 4. 35 + 0. 62 days and 5. 23+0. 88 days respectively. The lipiodol was mainly excreted by kidney, 2.6%-5. 7% of the infused dosage per day. A small amount of the lipiodol was excreted by feces, 0. 01 % of the infused cosage per day. It was considered that the hepatic artery infusion of 131 I-Lipiodol does no damage to other organs.